1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BMS's Abecma Faces J&J Threat Despite Pivotal Success In Earlier Myeloma Setting

Both Rivals Tout Blockbuster Potential

 
• By Ayisha Sharma

The US major’s CAR-T therapy is likely to win a label expansion to the large third-line-plus myeloma setting following positive Phase III data but a rival candidate from J&J could nab more of the market.  

Myeloma multiplex leukemia cancer 3d color render illustration isometric view
More Than 35,000 New Cases Of Multiple Myeloma Are Expected In 2023 • Source: Shutterstock

Bristol Myers Squibb Company’s Abecma has hit the mark in a pivotal multiple myeloma trial in patients with fewer lines of therapy than its current label but some analysts believe Johnson & Johnson’s rival CAR-T therapy Carvykti could steal its thunder.

In 2021, Abecma (idecabtagene vicleucel) became the first CAR-T therapy approved for relapsed or refractory multiple myeloma patients who had received at least four prior lines of treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.